思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 2025年6月， 精准肿瘤学企业Caris Life Sciences 正式向美国证券交易委员会（SEC）提交招股说明书，计划在纳斯达克上市，股票代码为"CAI"。 本次IPO预计募资约 4.235亿美元（约合30亿人民币），发行约2,350万股股票，定价区间为每股16-18美元。 上市完成后，公司估值或将超过 52亿美元。 这家总部位于德克萨斯州的分子诊断企业，过去十年累计融资已近20亿美元。2025年初，公司刚完成一笔 1.68亿美元增长资本融资 ，由Braidwell LP领投。 本次IPO是其资本路径中的又一关键节点，也标志着其在精准肿瘤学平台商业化、全球化布局方面的进一步推进。 # 四 大 产 品 构 成 精 准 诊疗 平 台 骨 架 ， 覆 盖 组 织 、 血液 与 多 重 突 变 维 度 Caris当前围绕肿瘤样本分析构建了四大主力产品线，分别针对不同样本来源与检测深度需求展开布局 ...

Enliven Therapeutics (ELVN) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 It's your Speaker1 day. Just grinding through this. Speaker0 It's fine. Yeah. It's gonna run around. It's like a barn. But it's good though. All set? Yeah. Okay. Hi, everyone. My name is Maury Raycroft and one of the biotech analysts at Jefferies. I'm happy to introduce Sam Kintz, the CEO of Enliven Therapeutics. Thanks for joining us today, Sam. And we're gonna do fireside chat format. So maybe for those who are new to the story ...

Core Insights - ITM Isotope Technologies Munich SE has elected Dr. Barbara Weber to its Supervisory Board, effective May 01, 2025, enhancing the board's expertise in advancing its radiopharmaceutical pipeline [1][2] - Dr. Weber brings over 25 years of experience in biotech and pharmaceutical industries, having held leadership roles at major companies and founded Tango Therapeutics [1][4] - The company is focused on developing its lead Phase 3 candidate, n.c.a. 177Lu-edotreotide (ITM-11), and expanding its pipeline of radiopharmaceuticals [1][3] Company Overview - ITM is a leading radiopharmaceutical biotech company dedicated to developing therapeutics and diagnostics for hard-to-treat tumors, aiming to improve patient outcomes through precision oncology [5] - The company has a broad pipeline that includes multiple Phase 3 studies, leveraging high-quality radioisotopes combined with various targeting molecules [5] Leadership and Expertise - Dr. Weber's background includes significant achievements in oncology drug development, including leading clinical studies that resulted in FDA approvals for several drugs [4] - As a physician-scientist, Dr. Weber emphasizes the potential of targeted radiopharmaceutical therapy to enhance precision oncology treatment [3]